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Abstract: Collapsin response mediator protein 2 (CRMP2), traditionally regarded as an axon/dendrite growth and 
guidance protein, plays an important role in the regulation of both post- and pre-synaptic Ca2+ channels, such as 
N-methyl-d-aspartate receptors (NMDARs). The Ca2+ channel-binding domain 3 (CBD3) peptide derived from CRMP2 
has recently emerged as a Ca2+ channel blocker, suppressing neuropathic pain in a spared nerve injury (SNI) model 
when linked to the transduction domain of HIV TAT protein and reduced neuronal death in a middle cerebral artery 
occlusion model and a traumatic brain injury (TBI) model. The present study aimed to examine the neuroprotective 
effects and biochemical mechanisms of ST2-104 (a non-arginine-conjugated CBD3 peptide) in an Aβ25-35-induced 
Alzheimer’s disease (AD) rat model. This study demonstrated that CRMP2 and NMDARs subunit NMDAR2B form 
a direct biochemical complex, which regulates NMDAR activity in a rat model. ST2-104 peptide given via tail vein 
injections significantly reduced spatial learning and memory impairment. ST2-104 relieved neuronal injuries by sup-
pressing expression of NMDAR2B and p-CRMP2 and increasing expression of CRMP2 in the hippocampus. Remark-
ably, ST2-104 attenuated levels of intracellular Ca2+ by disrupting the interaction between p-CRMP2 and NMDAR2B. 
Taken together, these findings support ST2-104 as a novel neuroprotective agent, potentially representing a novel 
direction for a therapeutic targeting channel in AD.
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Introduction
Alzheimer’s disease (AD) is an age-related pro-
gressive neurodegenerative disorder, charac-
terized by learning, spatial memory, and cogni-
tive dysfunction [1]. Main pathological changes 
include a decrease in synapses and neurons, 
amyloid beta protein deposition, and neurofi-
brillary tangles in the cortex, especially in the 
hippocampus [2, 3]. Current treatments cannot 
effectively improve the manifestation and block 
the progression of the disease [4]. Therefore, 
creating a new therapeutic strategy is neces-
sary for treatment of AD. 
Glutamate receptors, in particular NMDARs, 
are widely distributed in the hippocampus [5]. 
NMDARs can mediate many functions, includ-
ing physiological functions and pathological 
damage [6]. A growing body of literature has 
shown that Aβ deposition can act directly on 
NMDARs, leading to continuous NMDAR activa-
tion and eventual neural degeneration [7, 8]. 
This is because the promotion of Ca2+ influx 
through NMDARs may lead to intracellular Ca2+ 
overload in the postsynaptic neuron, the in- 
hibition of synaptic function, long term poten- 
tiation (LTP) exception, and cell death [9-11]. 
Therefore, NMDAR dysfunction plays a crucial 
role in the pathogenesis of AD. Targeting NM- 
DARs is a promising strategy for AD. It was con-
firmed that the activation of NMDARs can be 
regulated by various factors [12]. CRMP2, an 
abundant brain-enriched protein, is a novel 
binding partner of NMDARs, which is highly 
phosphorylated by CDK5 and GSK3β in AD 
brains [13, 14]. It was shown that the phos- 
phorylation of CRMP2 can strengthen the inter-
action between CRMP2 and NMDARs, causing 
excessive NMDARs activation, whereas block-
Neuroprotection of ST2-104 in Aβ25-35-induced AD
2231 Int J Clin Exp Med 2019;12(3):2230-2242
ing the combination of CRMP2 and NMDARs 
or knocking out CRMP2 could protect neurons 
from cerebral ischaemia and brain trauma [15, 
16]. In summary, the present study hypothesiz-
es that CRMP2/NMDAR interactions may play 
an important role in AD and that the modula-
tion of NMDARs by CRMP2 may have a protec-
tive effect on neurons.
CRMP2-derived peptide (namely ST2-104) is a 
non-arginine (R9)-conjugated CBD3 peptide. Its 
molecular weight is 3056.6 g/mol. It has been 
confirmed that ST2-104 is a neuroprotective 
peptide in glutamate-mediated neurotoxicity by 
blocking the combination of CRMP2 and NM- 
DARs in brain trauma and cerebral haemor-
rhages. It has been shown that ST2-104 exhib-
its a suppressive effect in rats with peripheral 
neuropathy, whereas the effects of ST2-104 
on AD have not been fully certified. Further 
investigation is urgently needed.
It was hypothesized that Aβ25-35 enhances lev-
els of p-CRMP2, which intensively interacts 
with NMDARs leading to the hyperactivation of 
NMDARs. Hyperactive NMDARs lead to an ex- 
cessive influx of Ca2+ ions that, in turn, lead to 
the disorder of intracellular calcium homeosta-
sis and cell death following excitotoxicity. 
Based on these results, this study proposed a 
model that explains the roles of CRMP2 in the 
regulation of NMDARs and elucidates the fea-
sible mechanisms of ST2-104 neuroprotective 
effects.
Materials and methods
Materials
Aβ25-35 was purchased from Sigma-Aldrich 
(A4559; St. Louis, USA). ST2-104 was synthe-
sised by Yaoqiang Biological Company (Jiang- 
su, China). Memantine hydrochloride was obta- 
ined from H. Lundbeck A/S (Denmark). Primary 
antibodies against GAPDH (ab37168), NMDA- 
R2B (ab93610), NMDAR1 (ab52177), CRMP2 
(ab129082), and pCRMP2 (ab193226) were 
purchased from Abcam (Cambridge, MA, USA). 
Secondary antibodies, NP-40 lysis buffer, BCA 
protein assay kit, DAB chromogen kit, protein 
A/G agarose beads, Fluo-3 AM, and D-Hank’s 
solution were purchased from the Beyotime 
Institute of Biotechnology (Shanghai, China). 
PVDF membranes and western ECL substrate 
were purchased from Bio-Rad (USA). RPMI-
1640 medium was purchased from Gibco 
(Shanghai, China). Foetal bovine serum was 
purchased from Biological Industries (04-001-
1ACS; Israel).
Animals
Male Wistar rats (280-310 g) were purchased 
from the Animal Experimental Center of Jilin 
University. The rats were controlled in an ani-
mal house with a temperature of 22 ± 2°C and 
humidity of 60% ± 5%, with a 12-hour light/
dark cycle. Rats were provided with free ac- 
cess to food and water. Rats were randomly 
separated into five groups (n=10 in each gro- 
up): Con group, Model group (Aβ25-35 15 nmol), 
ST2-104 (ST2-104 3 or 15 mg/kg + Aβ25-35 15 
nmol) groups, and Memantine (memantine hy- 
drochloride 3 mg/kg + Aβ25-35 15 nmol) group. 
Cell culture and treatment
Human neuroblastoma cell line SH-SY5Y was 
purchased from KeyGen Biotech (Jiangsu, 
China). These cells were verified to be of hu- 
man origin by hybridization of human DNA 
probes to SH-SY5Y genomic DNAs and control 
DNAs on nylon membrane. Cells were cultured 
in RPMI-1640 medium supplemented with 10% 
foetal bovine serum in a saturating humidified 
incubator with 5% CO2 at 37°C. To study the lev-
els of intracellular free Ca2+, cells were seeded 
into 6-well plates at a density of 2×105 cells/
mL. Upon reaching 70% confluence, cells were 
treated with 3 µM Aβ25-35 for 24 hours to induce 
excitatory damage. Cells were pre-treated with 
doses of ST2-104 (1, 3, or 10 µM) for 0.5 hours, 
then 3 µM Aβ25-35 was added to the medium for 
24 hours of co-incubation.
Aβ aggregation
Aβ25-35 was dissolved in 1% acetic acid and 
diluted in PBS to a final concentration of 2 
µg/µl and 1 mM, then incubated at 37°C for 7 
days to obtain aggregated Aβ25-35. Aggregated 
Aβ25-35 was sub-packaged with an EP tube and 
stored at -20°C for future use.
Surgery procedure and treatment
A rat model of AD was established using a sin-
gle dose of Aβ25-35 via intracerebroventricular 
injections. Briefly, rats were anesthetized with 
10% chloral hydrate (350 mg/kg) by intraperi-
toneal injections. Rats were then fixed onto a 
stereotaxic apparatus (Ward life technology 
co., LTD). The skull was exposed and a bregma 
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was located. The injection coordinates were 
1.8 mm lateral, 1.08 mm posterior, and 3.8 
mm ventral to the bregma. A hole (diameter 1.0 
mm) was drilled into the skull to expose the lat-
eral ventricles. Rats in the model group and 
treatment group received injections in both lat-
eral ventricles using a micro-syringe. The injec-
tion volume of Aβ25-35 for each rat was 8 µL (15 
nmol). After the injection, the needle was left 
for 10 minutes and removed slowly. Rats in the 
sham group received an equivalent volume of 
normal saline. During surgery, the rectal tem-
perature of the rats was maintained at 37°C. 
After surgery, the incision was sutured. The ani-
mals were returned to their cages and kept 
warm until they recovered consciousness. 
Rats in the drug intervention groups were intra-
venously administered ST2-104 (3 or 15 mg/
kg) and memantine hydrochloride (3 mg/kg) 
from day 2 to day 11. The Con group and Model 
group were administered saline in parallel. All 
animal procedures were approved by the Ethics 
Committee for the Use of Experimental Animals 
of Jilin University. The experimental schedule is 
shown in Figure 1. 
Morris water maze test
Morris water maze tests were performed from 
days 12 to 16. A circular black painted pool 
(150 cm in diameter, 30 cm in depth) was ran-
domly divided into four quadrants. The pool 
was filled with water maintained at 22°C ± 
0.5°C. An invisible escape platform (10 cm in 
diameter) was submerged 1 cm under the 
water surface in one quadrant. During the pro-
cess of training, the platform remained in a 
fixed location. Rats were trained for 5 consecu-
tive days, five trials per day. During each trial, 
rats were placed into the water from random 
starting points facing the pool wall until they 
found a hidden platform. Escape latency, the 
time needed to climb up the platform, was 
measured. If the rat could not find the platform 
within 120 seconds, it was guided to the plat-
camera positioned over the pool. The number 
of crossings over the original platform qua- 
drant and the time spent in the target quadr- 
ant were measured and analyzed using the 
Super Maze Morris software (Shanghai Soft- 
maze Information Technology Co. Ltd., Shang- 
hai, China). Behaviour tests were performed by 
2 investigators blinded to the experimental 
groups.
Brain tissue preparation
After the Morris water maze test, all rats were 
sacrificed by an overdose of 10% chloral hyd- 
rate (600 mg/kg). This was the primary method 
of euthanasia employed. Their brains were 
removed immediately. The hippocampi of the 
rats were dissected, rapidly frozen in liquid 
nitrogen, and stored at -80°C until the assay. 
For histological and immunohistochemical sta- 
ining, animals were perfused with 0.9% normal 
saline (100 mL), followed by 4% paraformalde-
hyde (pH 7.35, 350 mL). Brains were then 
removed and further fixed with 4% paraformal-
dehyde at 4°C until slicing. 
Histological and immunohistochemical stain-
ing
Brain tissues were embedded with paraffin and 
cut into 5-µm serial coronal sections. For histol-
ogy, sections containing the hippocampus were 
hydrated and stained with haematoxylin and 
eosin solution. They were then dehydrated and 
finally cover slipped. For immunohistochemis-
try, sections were treated with 3% H2O2 for 5 
minutes and blocked with 5% normal goat 
serum at room temperature for 30 minutes. 
Sections were then incubated with primary 
antibodies [p-CRMP2 (ab193226), CRMP2 
(ab129082), NMDAR1 (ab52177), NMDAR2B 
(ab93610), 1:500; Abcam] overnight at 4°C, 
washed with PBS, and further incubated with 
biotinylated anti-mouse anti-rabbit secondary 
antibodies (1:2,000; Beyotime) for 1 hour at 
room temperature. After washing with TBS 
form and escape latency was 
recorded as 120 seconds. On 
day 16, rats were subjected to 
a space probe test. For this 
test, the platform was remo- 
ved and the rats were permit-
ted to search for the platform 
for 120 seconds. During the 
Morris water maze tests, be- 
haviour was monitored with a 
Figure 1. Experimental schedule and time-line of drug treatment.
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three times, sections were visualized using a 
DAB chromogen kit (Beyotime, Shanghai, China) 
for 10 minutes at room temperature. The sec-
tions were observed under a light microscope 
and 5 random fields in each section were ana-
lyzed using Image Pro Plus 6.0 software. For 
negative controls, primary antibodies were 
replaced by PBS.
Western blot analysis
Brain tissues from rat hippocampi were homog-
enized with lysis buffer (Beyotime, Shanghai, 
China). Protein concentrations were determin- 
ed using a BCA protein assay kit (Beyotime, 
Shanghai, China). All samples were diluted in 
loading buffer (Beyotime, Shanghai, China). 
Thirty micrograms of protein were run on 10% 
SDS-PAGE and subsequently transferred onto 
PVDF membranes (Bio-Rad). The membranes 
were incubated with 5% non-fat milk in TBST 
(10 mM Tris-HCl, 150 mM NaCl, and 0.1% 
Tween-20 (v/v)) for 2 hours at room tempera-
ture, then incubated overnight at 4°C with 
the primary antibodies [GAPDH (ab37168), 
p-CRMP2 (ab193226), CRMP2 (ab129082), 
NMDAR1 (ab52177), NMDAR2B (ab93610), 
1:1,000; Abcam]. Membranes were incubated 
at room temperature for 2 hours with the 
secondary antibody (anti-rabbit or anti-mouse 
IgG, 1:1,000; Beyotime). Protein bands were 
visualized with the ECL reagent using the GE- 
NE Imaging system. Intensities of the protein 
bands were analyzed using Quantity One 
software.
Co-immunoprecipitation analysis
Rat hippocampal tissues were homogenized in 
NP-40 lysis buffer (Beyotime, Shanghai, China). 
Protein was quantified with a BCA kit. Two 
micrograms of anti-NMDAR2B (ab93610; Ab- 
cam) primary antibody was added to the lysate 
(500 µg) and rotated at 4°C for 2 hours. Protein 
A/G agarose beads were added, then the mix-
ture was rotated overnight at 4°C. The beads 
were washed with PBS five times and then 
resuspended in loading buffer and boiled for 5 
minutes. After centrifugation for 5 minutes, the 
supernatant was processed by immunoblotting 
using an anti-p-CRMP2 (ab93610; 1:1,000; Ab- 
cam) antibody and proper second antibody. 
Intracellular free Ca2+ detection
Intracellular free Ca2+ was detected using fluo-
rescent dye Fluo-3 AM (Beyotime, Shanghai, 
China). It can easily permeate cells but not bind 
Ca2+, then be readily resolved into Fluo-3 by 
intracellular esterase. Having combined with 
Ca2+, the Fluo-3 emits strong fluorescence at 
an excitation wavelength of 488 nm. SH-SY5Y 
cells in 6-well plates were loaded with Fluo-3 
AM (5 µM) in D-Hank’s balanced salt solution in 
incubator for 30 minutes. Treated cells were 
collected and washed three times with D-Hank’s 
balanced salt solution. Resulting fluorescence 
was detected by flow cytometer (Bio-Rad) with 
an emission wavelength of 525 nm and an exci-
tation wavelength of 488 nm.
Statistical analysis
Experimental data are expressed as the mean 
± S.E. Statistical analyses were performed by 
one-way analysis of variance (ANOVA) and 
Tukey’s statistics using Prism 5. Data are con-
sidered statistically significant when P<0.05.
Results
Protective effects of ST2-104 against Aβ25-35-
induced spatial learning and memory impair-
ment in rats
The effects of ST2-104 (3 or 15 mg/kg, iv.) on 
spatial learning and memory in Aβ25-35-induced 
rats were investigated using the Morris water 
maze test. Escape latency reductions, day by 
day, reflected learning with regards to long-term 
memory. Compared with the Control group, 
escape latencies were significantly increased 
in the Model group, (P<0.01). The increased 
escape latency by Aβ25-35 was significantly 
decreased in the ST2-104 (3 or 15 mg/kg) plus 
Aβ25-35 group, compared to the Model group 
(P<0.01, Figure 2A). In probe trials, a signifi-
cant decrease in the number of rats crossing 
over the original platform was recorded in the 
Aβ25-35 oligomer-induced rats, compared with 
the Control rats (P<0.01), and recovered by 
treatment with ST2-104 (3 or 15 mg/kg) (P< 
0.05, P<0.01, Figure 2C). In addition, ST2-104-
treated rats spent significantly more time in the 
target quadrant than the Model rats (P<0.01, 
Figure 2B). These data demonstrate that treat-
ment with aggregated Aβ25-35 resulted in the 
impairment of spatial learning and memory, 
while treatment with ST2-104 (3 or 15 mg/kg) 
significantly improved Aβ25-35-induced memory 
loss. Memantine hydrochloride is an antagonist 
of NMDAR used as positive control in the inves-
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tigation. The effectiveness of ST2-104 was in 
accord with that of memantine hydrochloride at 
3 mg/kg.
ST2-104 inhibited histopathological damage of 
the hippocampus in Aβ25-35-induced rats
H&E staining was conducted to evaluate neuro-
nal injuries in Aβ25-35-induced rats. In contrast 
to the Control group, obvious histopathological 
damage was observed in the hippocampi from 
the Model group. Neuronal loss was found in 
the CA1 region and the pyramidal layered struc-
ture was broken. Hippocampus CA1 areas in 
the Model group appeared to have a loose 
arrangement of neurons. These abnormalities 
were attenuated by ST2-104 treatment (Figure 
3A). The number of normal neurons in the CA1 
region of the hippocampus was counted under 
a light microscope. It was found that the aver-
age number of normal pyramidal cells in the 
Model group was lower than the Control group. 
Moreover, ST2-104 (3 or 15 mg/kg, iv.) treat-
ment significantly increased the number of nor-
mal pyramidal cells (P<0.01, Figure 3B).
ST2-104 suppressed NMDAR2B in the hippo-
campus of Aβ25-35-induced rats
To investigate the neuroprotective mechani- 
sms of ST2-104, NMDAR1/NMDAR2B protein 
expression in hippocampal CA1 neurons was 
tested by immunohistochemistry and Western 
blotting. Regarding immunohistochemistry, as 
shown in Figure 4, the optical density of NM- 
DAR2B was significantly higher in the Model 
group than in the control group, indicating that 
the number of NMDAR2B-positive neurons was 
increased. Compared with the Model group, 
treatment with ST2-104 (15 mg/kg) notably 
decreased the number of NMDAR2B-positive 
cells in the hippocampus (P<0.01, Figure 4B, 
4D). In contrast, NMDAR1-positive neurons 
were not significantly increased in the Model 
group and ST2-104 treatment did not show a 
significant alteration in NMDAR1-positive neu-
rons (Figure 4A, 4C, P>0.05). As shown in 
Figure 4F, the relative density of NMDAR2B of 
model rats was significantly increased. ST2-
104 inhibited the effects of Aβ25-35 on levels of 
NMDAR2B (P<0.05). In addition, the relative 
density of NMDAR1 was not significantly in- 
creased in the Model group and ST2-104 treat-
ment did not show a significant alteration in 
NMDAR1-positive neurons (Figure 4E). Results 
suggest that neuroprotection of ST2-104 was 
partly mediated by the downregulation of the 
NMDAR2B receptor, but not the NMDAR1 
receptor, in the hippocampi of Aβ25-35-induced 
rats.
ST2-104 increased expression of CRMP2 and 
reduced expression of p-CRMP2 in the hippo-
campi of Aβ25-35-induced rats
To investigate whether ST2-104 protects neu-
rons against Aβ25-35-induced injuries by enhanc-
ing CRMP2 and reducing p-CRMP2, this study 
measured expression of p-CRMP2/CRMP2 pro-
tein in the hippocampus. As seen in Figure 5A 
Figure 2. The effects of ST2-104 on Aβ25-35-induced cognitive impairment. A. Quantitative analysis of latency period. 
B. Time spent in the target quadrant. C. Number of crossings over original platform. D. Localization trial path-
way. Data are shown as mean ± standard deviation from at least three independent experiments. *P<0.05 and 
**P<0.01 vs. control group; #P<0.05 and ##P<0.01 vs. Model group. n=10.
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Figure 3. ST2-104 increased the number of normal neurons in the hippocampus of Aβ25-35-induced rats. A. HE stain-
ing. B. The number of normal neurons in the CA1 region of hippocampus was counted under a light microscope 
(magnification 200×). Data are shown as the mean ± standard deviation. ##P<0.01 vs. Con; **P<0.01 vs. Model. 
n=10.
and 5F, CRMP2 appeared to be localized in 
both the plasma membrane and cytoplasm, 
while neurons positive for CRMP2 were signifi-
cantly decreased in the Model group, compared 
to the control group (P<0.01). This pattern of 
expression was significantly reversed by ST2-
104 treatment relative to the Model group 
(P<0.05). As shown in Figure 5B and 5G, both 
Western blot and immunochemical staining 
showed that pCRMP2 was attenuated after 
being induced and upregulated by ST2-104 
treatment. 
ST2-104 disrupted the interaction of p-CRMP2/
NMDAR2B in the hippocampus of Aβ25-35-
induced rats
To confirm the interactions of p-CRMP2/NM- 
DAR2B, immunoprecipitation analysis was per-
formed. As shown in Figure 6, an interaction 
between p-CRMP2 and NMDAR2B was notably 
strengthened in Aβ25-35-induced rats. ST2-104 
disrupted the p-CRMP2-NMDAR2B complex. 
Inhibition of NMDAR2B activity by TAT-CBD3 
suggests a direct interaction between p-CR- 
MP2 and NMDAR2B. These experiments were 
focused on the interaction of p-CRMP2 with 
NMDAR2B because this type of NMDAR is pre-
dominantly involved in excitotoxicity. It is possi-
ble that p-CRMP2 upregulates NMDAR activity 
by binding to the NMDAR2B subunit and that 
TAT-CBD3-mediated dissociation of p-CRMP2 
from NMDAR2B leads to diminution of NMDAR 
activity.
ST2-104 suppressed levels of intracellular free 
Ca2+ concentrations in Aβ25-35-induced SH-SY5Y 
cells
Dysregulation in intracellular free Ca2+ has 
been recognized as one of the factors for cell 
injury and death [17, 18]. With this in mind, 
Fluo-3 AM was used to detect the effects of 
ST2-104 on intracellular free Ca2+ in SH-SY5Y 
cells. As shown in Figure 7, there were dramati-
cally elevated Ca2+ levels in SH-SY5Y cells treat-
ed with Aβ25-35 compared with control cells or 
cells treated with ST2-104. With increasing 
ST2-104 concentrations, the decrease in Ca2+ 
levels were more evident. Results indicate that 
the neuroprotective effects of ST2-104 were 
related to intracellular Ca2+ homeostasis.
Neuroprotection of ST2-104 in Aβ25-35-induced AD
2236 Int J Clin Exp Med 2019;12(3):2230-2242
implicated in many neurological diseases, in- 
cluding AD, cerebral ischemia and strokes, and 
neuroinflammation [23-25]. CRMP2 phosphory-
lation causes microtubule dissociation and 
axonal outgrowth arrest [26]. Hyperphosphory- 
lation of CRMP2 is an early event in the de- 
velopment of AD but not a common feature 
to other neurodegenerative diseases, perhaps 
suggesting that it could be an initially essential 
inducement and therapeutic target for AD [27-
Discussion
CRMP2 is an intracellular phosphoprotein, 
known as a neurite extension-promoting neu- 
ronal molecule, implicated in the advance of 
the neuronal growth cone [19-21]. CRMP-2 con-
tributes to axon formation by binding to tubulin 
heterodimers and promoting the assembly of 
microtubules with axonal growth and differen-
tiation [22]. CRMP2 has been reported to be 
Figure 4. Effects of ST2-104 
on the expression of NM-
DAR1/NMDAR2B in the hip-
pocampus of Aβ25-35 induced 
rats. A, B. The expression level 
of NMDAR1 was detected by 
immunohistochemical stain-
ing. C, D. Quantitative analy-
sis of NMDAR1/NMDAR2B 
expression. E. Representative 
immunoblots for the expres-
sion of NMDAR1/NMDAR2B. 
F, G. Densitometric analyses 
of the WB assays. Data are 
shown as the mean ± stan-
dard deviation. ##P<0.01, #P< 
0.05 vs. control group; **P< 
0.01, *P<0.05 vs. Model 
group. n=5.
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29]. This study demonstrated that the hyper-
phosphorylation of CRMP2 is an important fac-
tor in a Aβ25-35-induced AD rat model.
Small-molecule peptide aptamers targeting 
protein interactions have recently been pro-
posed as potential therapeutic agents for many 
diseases. Specific sequence peptides derived 
from endogenous proteins combine with conge-
netic sites of target proteins with high specific-
ity and affinity, thus selectively regulating the 
function of the target proteins complex [30]. 
Unlike gene knockouts and RNA interference, 
which attenuate the expression of target pro-
teins, peptide aptamers only regulate their rel-
evant function, resulting in the functional inter-
Figure 5. Effects of ST2-104 on the ex-
pression of p-CRMP2/CRMP2 in the 
hippocampus of Aβ25-35 induced rats. A, 
B. The level of p-CRMP2/CRMP2 expres-
sion was detected by immunochemistry. 
C, D. Quantitative analysis of p-CRMP2/
CRMP2 expression. E. Representative 
immunoblots for the expression of p-
CRMP2/CRMP2. F, G. Densitometric 
analyses of the WB assays. Data are 
shown as the mean ± standard deviation. 
##P<0.01 vs. control group; **P<0.01, 
*P<0.05 vs. Model group. n=5.
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ference of signaling pathways [31, 32]. ST2-104 
was conjugated CBD3 to the cell-penetrating 
peptide (CPP) R9 to structure a non-arginine 
(R9)-conjugated CBD3 (namely ST2-104) pep-
tide, which has superior cell membrane perme-
ability [33]. It has been shown that R9 is the 
most efficacious transduction domain protein 
in cells and that its toxicological effects are well 
tolerated by cells [34-36]. In the present study, 
ST2-104 remarkably improved spatial learning 
and memory in an Aβ25-35-induced AD rat model. 
Present findings also show that ST2-104 could 
attenuate expression of p-CRMP2 and increase 
expression of CRMP2 in the hippocampus.
Functional NMDARs are heterotetrameric com-
plexes formed of two NMDAR1 and two NM- 
DAR2 (NMDAR2A-D) subunits. They play a piv-
otal role in synaptic transmission plasticity for 
learning and memory and have been implica- 
ted in some neurological disorders [37]. NMD- 
AR1 is continuously and steadily expressed, 
whereas expression of four NMDAR2 subunits 
(NMDAR2A-D) is temporally and spatially regu-
lated in the brain [38]. The most studied NM- 
DAR2B has been found in postsynaptic densi-
ties and the expression of NMDAR2B is con-
stant and prominent within hippocampal CA1 
[39, 40]. Overexpression of NMDAR2B in the 
forebrain has been previously shown to incre- 
ase sensitivity to inflammatory pain [41]. Exce- 
ssive calcium influx through overactive NM- 
DARs can lead to excitotoxic neuronal death, 
thus suppression of overactive NMDARs has 
been shown to be neuroprotective [42]. Conti- 
nuous activation of NMDARs has been recent- 
ly implicated in AD related to synaptic dysfunc-
tion [43]. Aβ has been reported to trigger ab- 
normal NMDARs-mediated Ca2+ influx, which 
may induce defective Ca2+ homeostasis, lead-
ing to excitotoxicity in neurons [44]. Additionally, 
Aβ reduces surface expression of NMDAR sub-
unit protein NMDAR1 [45]. Aβ induces early 
neuronal dysfunction mediated by the exces-
sive activation of NMDARs subunit protein NM- 
DAR2B in hippocampal slices and primary neu-
ronal cultures of mouse and rat [46]. Present 
findings demonstrate that Aβ25-35 signally upreg-
ulated the total expression level of NMDAR2B 
protein, but not NMDAR1, in Aβ25-35-induced AD 
rats, suggesting that ST2-104 could attenuate 
expression of NMDAR2B.
Excessive Ca2+ influx through NMDARs, leading 
to activation of neurotoxic cascades, is thought 
to be a pivotal mediator of excitotoxicity be- 
cause many antagonists of these receptors 
have neuroprotection in animal models of TBI 
and ischaemia-induced excitotoxicity [47-49]. 
However, the neuroprotection of NMDAR antag-
onists in many human trials has not been seen 
in animal models, though alarming side effects 
have been reported [50-53]. In contrast, me- 
mantine, a non-competitive NMDARs antago-
nist, is able to attenuate excitotoxicity and pro-
tects neurons in various models [54-56]. In 
clinical trials, memantine has shown significant 
promise in aspects of cognition for AD patients 
[57, 58]. The limit of NMDARs antagonists 
underscores the need for new small-molecule 
drugs that can protect neurons from excitotox-
icity. Recent findings have suggested that 
NMDARs-interacting CRMP2 may be regarded 
as a novel neuroprotective target for various 
neurological disorders [12, 59]. Present find-
ings also suggest that Aβ25-35 treatment could 
strengthen the interaction of NMDAR2B and 
p-CRMP2, resulting in excessive NMDAR activi-
ty and neuronal excitotoxicity, whereas ST2-
104 could attenuate the interaction of p-CR- 
MP2 and NMDAR2B, decreasing concentra-
tions of intracellular Ca2+. 
In conclusion, the present study reveals that 
ST2-104 derived from CRMP2 protein is a novel 
neuroprotective peptide for treatment of AD. 
Present findings show that ST2-104 may exert 
its neuroprotective effects by decreasing ex- 
pression of NMDAR2B and p-CRMP2 and atten-
uating the interaction of p-CRMP2 and NM- 
DAR2B, thus decreasing intracellular Ca2+ lev-
Figure 6. The effects of ST2-104 on the combination 
of NMDAR2B and p-CRMP2 in the hippocampus of 
Aβ25-35-induced rats. Coimmunoprecipitation was 
performed with normal IgG or anti-NMDAR2B anti-
body to capture the complexes, followed by Western 
blotting with anti-p-CRMP2 antibody. The input was 
directly immunoblotted with anti-p-CRMP2 antibody.
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els. To further understand other possible bio-
chemical mechanisms of ST2-104, future stud-
ies will determine whether ST2-104 regulates 
cell surface trafficking and endocytosis of 
NMDAR2B and NMDAR1 in an Aβ25-35-induced 
cell injury model. Importantly, the significant 
function of ST2-104 peptides indicates that 
this novel approach has the potential for trans-
lation into an effective therapeutic approach 
for AD.
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